A Presurgical Study To Evaluate Molecular Changes That Occur In Human Non-Small Cell Lung Cancer Tissue After Short Term Exposure To PF-00299804
The A7471031 study was terminated on May 2, 2012. The decision for unplanned study
termination was triggered by feasibility of further conduct of this trial as only 22 of the
protocol-specified 75 patients were enrolled since the study initiated in February 2010.
Based on this low accrual rate it was determined that the study was highly unlikely to
complete accrual and provide meaningful data. The discontinuation of the study is not due
to any safety issue.
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
To identify the molecular changes which occur in human non-small cell lung cancer tissue after short-term exposure to PF-00299804 administered at 45 mg daily after a loading dose
Pfizer CT.gov Call Center
United States: Food and Drug Administration
|Pfizer Investigational Site||Birmingham, Alabama 35205|
|Pfizer Investigational Site||Blendora, California 91740|